RxDoctor Payments Data

John Frierson, MD

Interventional Cardiology · San Antonio, TXNPI 1326021015

Payments from drug & device makers

$2,755in general payments, 2019–2025

Across 98 payments — averaging $28.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$631
  • Medtronic$583
  • Cook Medical LLC$489
  • Novo Nordisk$232
  • Novartis$175
  • Boston Scientific$165
  • plus $479 from 9 others

What the payments were for

  • Travel & lodging$36213%
  • Food & beverage$2,39387%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,755 in reported general payments places this provider in the 15th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$356,952
Medicare patients
478
Services billed
3,308

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide173$185,334
EliquisApixaban137$174,713
MounjaroTirzepatide100$109,521
JanuviaSitagliptin Phosphate72$98,799
JardianceEmpagliflozin42$65,863
RybelsusSemaglutide25$63,223
EntrestoSacubitril/Valsartan44$59,943
WegovySemaglutide30$41,399
FarxigaDapagliflozin Propanediol37$37,642
TrulicityDulaglutide19$24,158
BrilintaTicagrelor14$16,476
Ezetimibe600$15,231
Diltiazem 12hr ErDiltiazem Hcl27$10,807
Metoprolol Succinate459$9,247
Atorvastatin Calcium679$7,181

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$232$289,955228 claims
PfizerEliquis$52$174,713137 claims
Lilly USA, LLCMounjaro, Trulicity$60$133,678119 claims
Boehringer IngelheimJardiance$127$65,86342 claims
NovartisEntresto$175$59,94344 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →